Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386396456> ?p ?o ?g. }
Showing items 1 to 90 of
90
with 100 items per page.
- W4386396456 abstract "<div>AbstractPurpose:<p>To report the safety and efficacy of ipatasertib (AKT inhibitor) combined with rucaparib (PARP inhibitor) in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with second-generation androgen receptor inhibitors.</p>Patients and Methods:<p>In this two-part phase Ib trial (NCT03840200), patients with advanced prostate, breast, or ovarian cancer received ipatasertib (300 or 400 mg daily) plus rucaparib (400 or 600 mg twice daily) to assess safety and identify a recommended phase II dose (RP2D). A part 1 dose-escalation phase was followed by a part 2 dose-expansion phase in which only patients with mCRPC received the RP2D. The primary efficacy endpoint was prostate-specific antigen (PSA) response (≥50% reduction) in patients with mCRPC. Patients were not selected on the basis of tumor mutational status.</p>Results:<p>Fifty-one patients were enrolled (part 1 = 21; part 2 = 30). Ipatasertib 400 mg daily plus rucaparib 400 mg twice daily was the selected RP2D, received by 37 patients with mCRPC. Grade 3/4 adverse events occurred in 46% (17/37) of patients, with one grade 4 adverse event (anemia, deemed related to rucaparib) and no deaths. Adverse events leading to treatment modification occurred in 70% (26/37). The PSA response rate was 26% (9/35), and the objective response rate per Response Criteria in Solid Tumors (RECIST) 1.1 was 10% (2/21). Median radiographic progression-free survival per Prostate Cancer Working Group 3 criteria was 5.8 months [95% confidence interval (CI), 4.0–8.1], and median overall survival was 13.3 months (95% CI, 10.9–not evaluable).</p>Conclusions:<p>Ipatasertib plus rucaparib was manageable with dose modification but did not demonstrate synergistic or additive antitumor activity in previously treated patients with mCRPC.</p></div>" @default.
- W4386396456 created "2023-09-03" @default.
- W4386396456 creator A5008731626 @default.
- W4386396456 creator A5015591858 @default.
- W4386396456 creator A5022584647 @default.
- W4386396456 creator A5022928424 @default.
- W4386396456 creator A5033372450 @default.
- W4386396456 creator A5034024396 @default.
- W4386396456 creator A5034433849 @default.
- W4386396456 creator A5041526616 @default.
- W4386396456 creator A5043781872 @default.
- W4386396456 creator A5048914713 @default.
- W4386396456 creator A5051581077 @default.
- W4386396456 creator A5051983148 @default.
- W4386396456 creator A5052353123 @default.
- W4386396456 creator A5059942977 @default.
- W4386396456 creator A5061095811 @default.
- W4386396456 creator A5065113263 @default.
- W4386396456 creator A5072168606 @default.
- W4386396456 creator A5078844914 @default.
- W4386396456 creator A5081365515 @default.
- W4386396456 creator A5085333470 @default.
- W4386396456 creator A5090641762 @default.
- W4386396456 date "2023-09-01" @default.
- W4386396456 modified "2023-10-17" @default.
- W4386396456 title "Data from A Phase Ib, Open-label Study Evaluating the Safety and Efficacy of Ipatasertib plus Rucaparib in Patients with Metastatic Castration-resistant Prostate Cancer" @default.
- W4386396456 doi "https://doi.org/10.1158/1078-0432.c.6762576.v2" @default.
- W4386396456 hasPublicationYear "2023" @default.
- W4386396456 type Work @default.
- W4386396456 citedByCount "0" @default.
- W4386396456 crossrefType "posted-content" @default.
- W4386396456 hasAuthorship W4386396456A5008731626 @default.
- W4386396456 hasAuthorship W4386396456A5015591858 @default.
- W4386396456 hasAuthorship W4386396456A5022584647 @default.
- W4386396456 hasAuthorship W4386396456A5022928424 @default.
- W4386396456 hasAuthorship W4386396456A5033372450 @default.
- W4386396456 hasAuthorship W4386396456A5034024396 @default.
- W4386396456 hasAuthorship W4386396456A5034433849 @default.
- W4386396456 hasAuthorship W4386396456A5041526616 @default.
- W4386396456 hasAuthorship W4386396456A5043781872 @default.
- W4386396456 hasAuthorship W4386396456A5048914713 @default.
- W4386396456 hasAuthorship W4386396456A5051581077 @default.
- W4386396456 hasAuthorship W4386396456A5051983148 @default.
- W4386396456 hasAuthorship W4386396456A5052353123 @default.
- W4386396456 hasAuthorship W4386396456A5059942977 @default.
- W4386396456 hasAuthorship W4386396456A5061095811 @default.
- W4386396456 hasAuthorship W4386396456A5065113263 @default.
- W4386396456 hasAuthorship W4386396456A5072168606 @default.
- W4386396456 hasAuthorship W4386396456A5078844914 @default.
- W4386396456 hasAuthorship W4386396456A5081365515 @default.
- W4386396456 hasAuthorship W4386396456A5085333470 @default.
- W4386396456 hasAuthorship W4386396456A5090641762 @default.
- W4386396456 hasConcept C121608353 @default.
- W4386396456 hasConcept C126322002 @default.
- W4386396456 hasConcept C126894567 @default.
- W4386396456 hasConcept C143998085 @default.
- W4386396456 hasConcept C197934379 @default.
- W4386396456 hasConcept C203092338 @default.
- W4386396456 hasConcept C2779984678 @default.
- W4386396456 hasConcept C2780192828 @default.
- W4386396456 hasConcept C31760486 @default.
- W4386396456 hasConcept C535046627 @default.
- W4386396456 hasConcept C71924100 @default.
- W4386396456 hasConceptScore W4386396456C121608353 @default.
- W4386396456 hasConceptScore W4386396456C126322002 @default.
- W4386396456 hasConceptScore W4386396456C126894567 @default.
- W4386396456 hasConceptScore W4386396456C143998085 @default.
- W4386396456 hasConceptScore W4386396456C197934379 @default.
- W4386396456 hasConceptScore W4386396456C203092338 @default.
- W4386396456 hasConceptScore W4386396456C2779984678 @default.
- W4386396456 hasConceptScore W4386396456C2780192828 @default.
- W4386396456 hasConceptScore W4386396456C31760486 @default.
- W4386396456 hasConceptScore W4386396456C535046627 @default.
- W4386396456 hasConceptScore W4386396456C71924100 @default.
- W4386396456 hasLocation W43863964561 @default.
- W4386396456 hasOpenAccess W4386396456 @default.
- W4386396456 hasPrimaryLocation W43863964561 @default.
- W4386396456 hasRelatedWork W2009096079 @default.
- W4386396456 hasRelatedWork W2114684119 @default.
- W4386396456 hasRelatedWork W2167331614 @default.
- W4386396456 hasRelatedWork W2568506988 @default.
- W4386396456 hasRelatedWork W2886193299 @default.
- W4386396456 hasRelatedWork W2889701300 @default.
- W4386396456 hasRelatedWork W3089163820 @default.
- W4386396456 hasRelatedWork W3177224496 @default.
- W4386396456 hasRelatedWork W4379280921 @default.
- W4386396456 hasRelatedWork W4384922324 @default.
- W4386396456 isParatext "false" @default.
- W4386396456 isRetracted "false" @default.
- W4386396456 workType "article" @default.